Creative Medical Technology Holdings announced that its pilot study of Ultrasome™, a proprietary cell‑free regenerative therapy for knee osteoarthritis, achieved a 93 % response rate, with patients reporting clinically meaningful improvements in mobility and pain reduction. The study, which used the company’s GMP‑manufactured CELZ‑201 (Olastrocel) as the source of biologic signaling, reported no serious adverse events, underscoring the safety profile of the cell‑free format.
The 93 % response rate is a striking indicator of efficacy for a high‑volume indication such as knee osteoarthritis, a condition that affects more than 30 million adults in the United States. The absence of serious adverse events further strengthens the case for Ultrasome™ as a safe, outpatient‑ready therapy. By converting CELZ‑201 into a cell‑free product, Creative Medical reduces manufacturing complexity, lowers costs, and enables off‑the‑shelf distribution—key advantages that could accelerate commercialization and broaden market reach.
Ultrasome™ is derived from CELZ‑201, which is currently being evaluated in the company’s FDA‑cleared ADAPT clinical trial. The pilot study’s success validates the company’s strategy to leverage its existing platform for scalable, cell‑free solutions, positioning Creative Medical to pursue a broader regenerative medicine portfolio that includes both cell‑based and cell‑free therapies.
CEO Timothy Warbington said, "This represents a significant evolution of our platform. By building on CELZ‑201, we are advancing a cell‑free regenerative approach that improves scalability and accessibility." He added, "We are entering a phase where execution and data generation will drive value. Our objective is to leverage our platform across both cell‑based and cell‑free therapies to deliver meaningful outcomes for patients while building long‑term shareholder value."
The pilot study milestone signals a critical step toward commercialization. With a high response rate and a favorable safety profile, Creative Medical can expand clinical execution, generate additional data, and explore commercialization pathways for Ultrasome™ in the knee osteoarthritis market. The result also reinforces the company’s broader pipeline strategy and its position within the growing trend of cell‑free regenerative therapies, which offer manufacturing and delivery advantages over traditional cell‑based products.
The announcement highlights Creative Medical’s progress in addressing a large, underserved market. Knee osteoarthritis treatment options are largely limited to symptom management and invasive procedures; a scalable, cell‑free therapy could capture significant market share and provide a competitive edge in the regenerative medicine space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.